The natural history and treatment of epilepsy in a murine model of tuberous sclerosis.
about
Potential for treatment of severe autism in tuberous sclerosis complexInflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex.Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complexImpaired social interactions and motor learning skills in tuberous sclerosis complex model mice expressing a dominant/negative form of tuberinImpaired astrocytic gap junction coupling and potassium buffering in a mouse model of tuberous sclerosis complex.Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex.Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.Excessive activation of mTOR in postnatally generated granule cells is sufficient to cause epilepsy.Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis.Rapamycin for treating Tuberous sclerosis and Autism spectrum disordersEffects of traumatic brain injury on reactive astrogliosis and seizures in mouse models of Alexander disease.Impact of corticosterone treatment on spontaneous seizure frequency and epileptiform activity in mice with chronic epilepsy.Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsiesTherapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice.Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex.Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation.Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference.Animal models of focal cortical dysplasia and tuberous sclerosis complex: recent progress toward clinical applications.Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation.Is epilepsy a preventable disorder? New evidence from animal models.Behavioral profiles of mouse models for autism spectrum disorders.Tuberous sclerosis and epilepsy: role of astrocytes.Aberrant Cortical Activity in Multiple GCaMP6-Expressing Transgenic Mouse Lines.Microglial activation during epileptogenesis in a mouse model of tuberous sclerosis complex.Abnormal Microglia and Enhanced Inflammation-Related Gene Transcription in Mice with Conditional Deletion of Ctcf in Camk2a-Cre-Expressing Neurons.Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an age-dependent manner.
P2860
Q27021739-6DC06B08-DEBC-4337-884A-CB36649E4B5FQ27308042-0A214FDB-D967-4A06-882C-ACD7D4DC797FQ28486250-BAF119E0-4C8F-4136-84EA-75B10FB0289EQ30459608-D5C70439-51B5-4688-A568-72E4D8011208Q30491063-6E1CB594-DA5B-448B-ADB0-33D5CC29C2CBQ30493205-013CE98F-373B-488C-AE63-093F1EC53A82Q30497818-2E662AC9-B128-4B88-973A-E7A28175C10BQ30525675-2E18C0E1-547C-4706-B3A3-13B96E850686Q30573030-EBEE8469-B402-41D2-B9E5-585D695BFC97Q33750454-7D24C1DC-0F40-4B96-B35F-815A1156B8CDQ34024856-EA96AE14-2064-4CE8-8AD6-B5B52613C1CCQ34183917-5A9A606F-842C-4951-816D-7D2585EF9889Q34430688-4DBC5CC8-0086-4DC6-A18A-B71429A55E24Q34498303-F71F63AF-02C8-44EF-B4D0-5EC397DDA5C8Q35028378-7828F45B-16A1-4CDF-A6D3-5FA8FC8CB96FQ35476371-EE1EBE0B-D7AE-4A3F-A529-CB91D25A6206Q36226071-902B6F1D-7A89-449D-8223-436B93A6F7D2Q36922578-A7A9549E-D076-4FFD-9544-42BE94342812Q37038637-A81721AC-FFFD-483E-B0FD-3BA8C9ACE476Q37598955-141B1609-4493-4B38-8CF6-53DD73B6A538Q37636466-A7766F27-F4B7-4B22-BA0B-AE91045F3EF7Q37755921-AE3E9F5E-F5B9-4A1D-AA24-248B0E8392D8Q37844007-A56D2F7A-DD0B-46F1-9FD5-FF1A127CF6D8Q37995965-F8E36867-7B49-4DC3-9C57-5274D3177911Q41712979-66CFD3EA-BC07-4BED-9323-9C171433D2F1Q42110691-B24389B6-AEDB-45A6-9729-155CD7BCA4F8Q47407107-A71C8476-4181-496C-8D30-95D6FB455E9AQ47567370-BB583557-E7AB-4CE1-9369-5B0CC8DF2AE5
P2860
The natural history and treatment of epilepsy in a murine model of tuberous sclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The natural history and treatment of epilepsy in a murine model of tuberous sclerosis.
@en
The natural history and treatment of epilepsy in a murine model of tuberous sclerosis.
@nl
type
label
The natural history and treatment of epilepsy in a murine model of tuberous sclerosis.
@en
The natural history and treatment of epilepsy in a murine model of tuberous sclerosis.
@nl
prefLabel
The natural history and treatment of epilepsy in a murine model of tuberous sclerosis.
@en
The natural history and treatment of epilepsy in a murine model of tuberous sclerosis.
@nl
P2093
P2860
P1433
P1476
The natural history and treatment of epilepsy in a murine model of tuberous sclerosis
@en
P2093
Ebru Erbayat-Altay
Ling-Hui Zeng
Michael Wong
P2860
P304
P356
10.1111/J.1528-1167.2007.01110.X
P577
2007-05-01T00:00:00Z